Dr Reddys Laboratories Ltd Financials
Company Logo

Dr Reddys Laboratories Ltd Financial Statement

Dr Reddys Laboratories Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue5977.30
Operating Expense4119.90
Net Profit1200.70
Net Profit Margin20.09
Earning Per Share14.41
EBIDTA1860.60
Effective Tax Rate19.61

Dr Reddys Laboratories Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual23,115.40
Operating Expenses Annual15,733.60
Operating Profit Annual8,385.20
Interest Annual109.90
Depreciation818.40
Net Profit Annual5,349.40
Tax Annual1,886.50

Dr Reddys Laboratories Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning201.40
Cash Flow from Operations4,225
Cash Flow from Investing-5,697.40
Cash Flow from Financing1,590.70
Cash Flow at the End319.70

Dr Reddys Laboratories Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)36.28
PBIT Margin (%)31.78
PBT Margin (%)31.49
Net PROFIT Margin (%)23.14
Return On Networth / Equity (%)20.15
Return On Networth /Employed (%)25.47
Return On Assets (%)18.51
Total Debt / Equity (X)0.08
Asset Turnover Ratio (%)0.80

Dr Reddys Laboratories Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual8,272.80
Total Current Assets Annual16,503
Non Current Assets Annual21,787.90
Total Shareholders Funds Annual28,856.60
Total Assets Annual38,290.90

Dr Reddys Laboratories Ltd Earning Calls

EPS (INR)

Expected

19.10

Reported

19.12

Surprise

0.10%

Dec 2024

EPS beaten by 0.10%

Sep 2024

EPS beaten by 0.12%

Jun 2024

EPS beaten by 0.16%

FAQS on Dr Reddys Laboratories Ltd Financials

As of Jul 7, 2025, Dr Reddys Laboratories Ltd has a market capitalization of 95,465.87 Cr. Value Research classifies it as a Large-Cap company.

Yes, Dr Reddys Laboratories Ltd is with a debt-to-equity ratio of 0.12.

In FY 2024 , Dr Reddys Laboratories Ltd recorded a total revenue of approximately 23,046.80 Cr marking a significant milestone in the company's financial performance.

Dr Reddys Laboratories Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.2% annually, respectively..

Dr Reddys Laboratories Ltd's current PE ratio is 17.85.

Dr Reddys Laboratories Ltd's ROCE averaged 21.5% from the FY ending March 2023 to 2025, with a median of 22.6%. It peaked at 23.1% in March 2024, reflecting strong capital efficiency over the period..

Dr Reddys Laboratories Ltd's latest EBIT is Rs. 7,345.80 Cr, surpassing the average EBIT of Rs. 5,680.60 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions